After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound

Nicole DeFeudis

Editor

More than any other year in recent memory, 2020 was a rollercoaster of highs and lows —mostly lows. Just ask San Francisco’s Nektar: Despite ditching …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Af­ter an up-and-down year, Nek­tar watch­es de­vel­op­ment head Wei Lin walk away as it pur­sues pipeline re­bound

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound